Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,393.99
+0.8%
+56.88
Arrow-Thin-Down
DJI
49,662.19
+0.1%
+65.22
Arrow-Thin-Down
NASDAQ
26,145.60
+1.3%
+339.40
Arrow-Thin-Down
Bitcoin
$80,224.00
+0.1%
+$58.50
Arrow-Thin-Down
AAPL
$293.55
+2.1%
+$6.11
Arrow-Thin-Down
AMZN
$272.10
+0.3%
+$0.93
Arrow-Thin-Down
GOOG
$396.50
+0.3%
+$1.20
Arrow-Thin-Down
META
$611.98
-0.8%
-$4.83
Arrow-Thin-Down
MSFT
$416.36
-1.0%
-$4.41
Arrow-Thin-Down
NVDA
$216.09
+2.2%
+$4.59
Arrow-Thin-Down
TSLA
$427.81
+3.9%
+$16.02
Most Active StocksDaily Stock GainersDaily Stock Losers
Climb Bio logo

Climb Bio

(NASDAQ) ELYM

Current PriceN/A
Market CapN/A
Since IPO (2021)-23%
5 YearN/A
1 Year+884%
1 Month+73%

Climb Bio Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

$52.79M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

ELYM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Climb Bio

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Aoife M. Brennan, MD

Website

www.climbbio.com

Headquarters

Redmond, WA 98053, US

ELYM Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-33%

Return on Capital

-42%

Return on Assets

-36%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$67.88M

EBITDA

$67.88M

Operating Cash Flow

$54.36M

Capital Expenditure

$186.00K

Free Cash Flow

$54.54M

Cash & ST Invst.

$101.08M

Total Debt

$541.00K

Climb Bio Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

9

N/A

Net Income

$13.72M

+34.0%

EBITDA

$15.21M

+33.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$109.08M

+11.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$216.00K

-32.3%

Short Term Debt

$263.00K

+69.7%

Return on Assets

-35.68%

N/A

Return on Invested Capital

-42.23%

N/A

Free Cash Flow

$14.38M

+6.8%

Operating Cash Flow

$14.38M

+6.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CKPTCheckpoint Therapeutics, Inc.
$4.26+0.00%
SCPHscPharmaceuticals Inc.
$5.67+0.00%
RVNCRevance Therapeutics, Inc.
$3.65+0.00%
VIGLVigil Neuroscience, Inc.
$8.05+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.45+0.07%
RXTRackspace Technology
$5.02+0.43%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.59-0.05%
EOSEEos Energy Enterprises
$7.59+0.19%

Questions About ELYM

What is the current price of Climb Bio?

Climb Bio is trading at N/A per share.

What is the 52-week range for Climb Bio?

Over the past 52 weeks, Climb Bio has traded between N/A and N/A.

How much debt does Climb Bio have?

As of the most recent reporting period, Climb Bio reported total debt of $479,000.

How much cash does Climb Bio have on hand?

Climb Bio reported $8.36M in cash and cash equivalents in its most recent financial results.

What is Climb Bio’s dividend yield?

Climb Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services